Phase II to Validate Use of the QuantraTM for Measuring Platelet Impairment

Charlottesville, VA – August 7, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced that it received a $1 million Phase II grant from the United States Department of the Air Force. The Phase II grant will help fund the development of the Quantra™  and the evaluation of its clinical utility in assessing coagulopathies in trauma.

“This grant validates the need for a fast, comprehensive and accurate point of care test to measure platelet impairment and guide treatment of critical bleeding in trauma settings,” said Francesco Viola, Chief Science Officer of HemoSonics. “These funds will support the continued development of our Quantra™  platform, designed to deliver actionable information to guide the management of critical bleeding and clotting in critical care settings.”